trans-2-(4-fluorophenyl)cyclopropanecarboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trans-2-(4-fluorophenyl)cyclopropanecarboxylic acid
• 英文别名: (1S,2S)-2-(4-Fluorophenyl)cyclopropanecarboxylic Acid；(1S,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid
• 化学式: C₁₀H₉FO₂
• 分子量: 180.179
• InChiKey: QJJWMUZHTDQZDW-BDAKNGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  trans-2-(4-fluorophenyl)cyclopropanecarboxylic acid 在 lithium aluminium tetrahydride 、 三乙基硼氢化锂 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 生成 trans-1-methyl-2-(4-fluorophenyl)cyclopropane
  参考文献：
  名称：

  Picosecond radical kinetics. Rate constants for ring openings of 2-aryl-substituted cyclopropylcarbinyl radicals

  摘要：

  The kinetics of ring openings of a series of eight (trans-2-arylcyclopropyl)methyl radicals (1) were studied by indirect kinetic methods using Barton's PTOC esters as radical precursors and reaction with PhSeH as the competition reaction. The substituents were CF3, F, Me, and OMe located on both the para and meta positions of the aromatic ring. Syntheses of the radical precursors and the products of the radical reactions are described. Kinetics were determined between -43 and 25 degrees C in four cases (CF, and OMe substituents) and at 0 and 25 degrees C in the other four cases. The rate constants at 25 degrees C ranged from 1.0 x 10(11) s(-1) (p-CH3) to 4.1 x 10(11) s(-1) (p-CF,). The relatively large acceleration of the p-CF3 group, ca. 2.5 times as fast as the parent system with Ar = Ph, correlates well with Adam's Delta D substituent parameters but not with other radical substituent parameters. These calibrated radical rearrangements provide a new set of ultrafast reactions that can be applied in mechanistic probe studies.

  DOI：

  10.1139/cjc-77-5-6-1123
• 作为产物：
  描述：

  3-(4'-氟苯基)-丙烯酸甲酯 在 palladium diacetate 、 sodium hydroxide 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 trans-2-(4-fluorophenyl)cyclopropanecarboxylic acid
  参考文献：
  名称：

  trans-2-Aryl-N,N-dipropylcyclopropylamines:  Synthesis and Interactions with 5-HT_1A Receptors

  摘要：

  Twelve N,N-dipropyl-substituted derivatives of trans-2-arylcyclopropylamine have been prepared and assayed for their ability to displace [H-3]-8-OH-DPAT from rat brain 5-HT1A receptors. The new derivatives include phenyl (7a), bromo- (7b) and fluorophenyl (7c-e), 2-methoxy-5-fluorophenyl (7h), and 2-hydroxy-5-fluorophenyl (7I) as well as trifluoromethylphenyl (7f) and 2,3-dichlorophenyl (7g) analogues. In the present series of compounds, electron-withdrawing substituents in the phenyl ring appear to decrease the affinity for 5-HT1A receptors. In contrast, electron-rich aryl groups, such as 2- or 3-thienyl (7j and 7k, respectively), provide compounds with high affinity. The additional bulk produced by the aromatic moiety in the 2-benzothienyl derivative 7i appears to be detrimental to 5-HT1A receptor affinity. The racemic mixtures of the interesting 7j and 7I were resolved into the enantiomers; 7j and 7I exhibited a high enantiomeric 5-HT1A receptor affinity ratio (75-fold and 100-fold, respectively). The enantiomers of 7j and 7I were evaluated in vivo by use of biochemical and behavioral tests in rats. Compound (LR,2R)-7j behaved as a partial agonist whereas (1R,2S)-7I appeared as an efficacious 5-HT1A receptor agonist, stimulating both autoreceptors and postsynaptic receptors.

  DOI：

  10.1021/jm9507136

文献信息

• KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：Imago Biosciences, Inc.

  公开号：US20160237043A1

  公开（公告）日：2016-08-18

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

  本文披露了新化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制KDM1A的方法，增加γ球蛋白基因表达的方法，以及诱导人类或动物主体中癌细胞分化的方法，用于治疗急性髓性白血病等疾病。
• [EN] AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS D'AMINE AGISSANT COMME BLOQUEURS DU CANAL POTASSIUM
  申请人：BIONOMICS LTD

  公开号：WO2012155199A1

  公开（公告）日：2012-11-22

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及一种在细胞中调节钾通道活性的化合物，特别是发现在T细胞中的Kv1.3通道的活性。该发明还涉及利用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的药物组合物以及其制备方法。
• Synthesis and in vitro evaluation of novel N-cycloalkylcarbamates as potential cholinesterase inhibitors
  作者：Eva Horáková、Pavel Drabina、Lenka Brůčková、Šárka Štěpánková、Katarína Vorčáková、Miloš Sedlák

  DOI：10.1007/s00706-017-2026-5

  日期：2017.12

  inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). All studied carbamates exhibited moderate inhibitory activity of both cholinesterases with values of IC50 in the range of 36.1–78.6 μM for AChE and 9.8–215.4 μM for BChE, respectively. These values are comparable with those values of inhibition obtained with the established drug rivastigmine. The cytotoxicity of all carbamates was evaluated

  摘要本文描述了一系列O-取代的N-环烷基氨基甲酸酯衍生物的制备和表征。测试了这些化合物作为乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE）的抑制剂。所有研究的氨基甲酸酯均显示出两种胆碱酯酶的中等抑制活性，IC 50值为AChE的范围为36.1–78.6μM，BChE的范围为9.8–215.4μM。这些值可与用已确定的药物卡巴拉汀获得的抑制值相当。使用标准的Jurkat细胞体外试验评估了所有氨基甲酸酯的细胞毒性。就其抑制活性以及可忽略的细胞毒性而言，许多已研究的氨基甲酸酯被认为是用于潜在医学应用的有前途的化合物。 图形概要
• [EN] PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C<br/>[FR] DÉRIVÉS DE PYRAZINE ET D'IMIDAZOLIDINE ET LEURS UTILISATIONS EN VUE DU TRAITEMENT DE L'HÉPATITE C
  申请人：GILEAD PHARMASSET LLC

  公开号：WO2012103113A1

  公开（公告）日：2012-08-02

  Disclosed herein are compounds useful for treating a viral infection, such HCV.

  本文披露了一些用于治疗病毒感染，如HCV的化合物。
• New Positive allosteric modulators of nicotinic acetylcholine receptor
  申请人：Eskildsen Jørgen

  公开号：US20130012530A1

  公开（公告）日：2013-01-10

  The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

  本发明涉及在治疗中有用的化合物，包括含有该化合物的组合物，以及包括给予该化合物的治疗疾病的方法。所涉及的化合物是尼古丁型乙酰胆碱α7受体的正向变构调节子（PAMs）。